Obtaining and analyzing plasmasamples from patients with non small cell lung cancer, referred for radiation treatment and/or chemotherapy

Obtaining and analyzing plasmasamples from patients with non small cell lung cancer, referred for radiation treatment and/or chemotherapy - ICD

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

NL-OMON

Registry ID

NL-OMON47175

Enrollment

Registered

2018-04-11

Start date

2017-04-25

Completion date

Unknown

Last updated

2024-02-28

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

non small cell lung cancer

Interventions

3 blood withdrawals of 25ml

Lung cancer

Non small cell

Plasma

Eligibility

Age

18 Years to 64 Years

Inclusion criteria

Inclusion criteria: • Participant is willing and able to give informed consent for participation in the trial. • Male or female, aged 18 years or above. • Diagnosed with non-small cell lung cancer • Scheduled to receive one of the following two therapeutic strategies: - Concurrent cisplatin-doublet chemotherapy and radiotherapy (minimal dose of 60 Gy in fractionated non-ablative doses) in patients with stage III NSCLC - SBRT for stage I NSCLC: 54Gy in 3 fractions, 48 Gy in 4 fractions or 60 Gy in 8 or 5 fractions • Is able and willing to comply with all trial requirements.

Exclusion criteria

Exclusion criteria: - Chronic use of corticosteroids, except when used as anti-emetics for chemotherapy or inhalers - NSAIDs taken until 5 days before radiotherapy or during radiation (low dose Aspirin at a maximum of 160 mg/day, is allowed) - Active auto-immune diseases - Immunosuppressive medication

Design outcomes

Primary

Measure	Time frame
Changes of relative protein expression / lipid profile for plasma / plasma-derived exosomes, linked to ICD	—

Secondary

Measure	Time frame
- Changes of relative protein expression, linked to Th1 / Th2 subsets - Changes of relative protein expression, linked to vascular damage	—

Countries

Belgium, Netherlands

Outcome results

None listed

Source: NL-OMON (via WHO ICTRP)